Breast Cancer Cells with PI3K Mutation or HER2 Amplification Depend on Akt Signaling
Author Information
Author(s): She Qing-Bai, Chandarlapaty Sarat, Ye Qing, Lobo Jose, Haskell Kathleen M., Leander Karen R., DeFeo-Jones Deborah, Huber Hans E., Rosen Neal
Primary Institution: Memorial Sloan-Kettering Cancer Center
Hypothesis
The study aims to determine the role of Akt activation in breast cancer and whether inhibiting Akt signaling is a feasible therapeutic approach.
Conclusion
Breast cancers with PI3K mutation or HER2 amplification are selectively dependent on Akt signaling, and inhibiting Akt is an effective treatment strategy.
Supporting Evidence
- Breast cancer cells with PIK3CA mutation or HER2 amplification are sensitive to the Akt inhibitor AKTi-1/2.
- Inhibition of Akt signaling leads to G1 arrest and apoptosis in sensitive breast cancer cells.
- Chronic treatment with AKTi-1/2 effectively suppresses tumor growth in vivo without significant toxicity.
Takeaway
Some breast cancer cells really need a specific signal to grow, and blocking that signal can stop them from growing.
Methodology
The study used a selective allosteric inhibitor of Akt kinase on breast cancer cell lines with specific genetic lesions to assess the effects of Akt inhibition.
Limitations
The study primarily focuses on specific breast cancer cell lines and may not generalize to all breast cancer types.
Statistical Information
P-Value
p<0.005
Statistical Significance
p<0.005
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website